Thanks for sharing. As others noted, this likely isn't a...

Thanks for sharing. As others noted, this likely isn't a leak but a broker/analyst assumption. My opinion is that at these prices there's money to be made in the short-medium term once FDA approvals start to drop. As for the result tomorrow, I have no idea what to expect. But my suspicion is that generics has seen a stabilization, specialty will be down, metrics will be up, and overall the result will be flat on first half or potentially slight improvement due to favorable FX movements in H2. I think the outlook for FY21 will be painted positive pending the launch of products pending FDA approval. I don't expect any guidance from the company as they never provide this which is part of the problem. Fingers crossed we are surprised to the upside - with the result and the outlook. Good luck all - I'm rooting for every single long term holder here!